Active substance
Losartan
- SFDA 17
- US FDA 27
- Health Canada 27
- US price lines 6
- NHS prices 4
- WHO EML 2
- Safety 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| AZAR 100 mg film-coated tablet | 100 mg | Film-coated tablet · Oral use | 30 Blister | SAR 47.50 | Generic · Prescription | COOPER PHARMA | Valid |
| AZAR 50 mg film-coated tablet | 50 mg | Film-coated tablet · Oral use | 30 Blister | SAR 45.35 | Generic · Prescription | COOPER PHARMA | Valid |
| COZAAR | 50 mg | Film-coated tablet · Oral use | 28 Blister | SAR 45.35 | NCE · Prescription | N.V. Organon | Valid |
| COZAAR 100 mg film-coated tablet | 100 mg | Film-coated tablet · Oral use | 28 Blister | SAR 52.80 | Generic · Prescription | N.V. Organon | Valid |
| LACINE 50MG F.C. TABLETS | 50 mg | Film-coated tablet · Oral use | 30 Blister | SAR 42.20 | Generic · Prescription | The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM) | Valid |
| Lacine | 50 mg | Film-coated tablet · Oral use | 1000 Blister | SAR 544.30 | Generic · Prescription | The Jordanian Pharmaceutical Manufacturing Medical Equipment Co. Ltd. (JPM) | Valid |
| Osart | 100 mg | Film-coated tablet · Oral use | 28 Blister | SAR 47.50 | Generic · Prescription | Elixir Pharmaceutical Company LLC | Valid |
| Osart | 50 mg | Film-coated tablet · Oral use | 30 Blister | SAR 40.80 | Generic · Prescription | Elixir Pharmaceutical Company LLC | Valid |
| SARTAN 100 mg Film coated Tablets | 100 mg | Film-coated tablet · Oral use | 30 Blister | SAR 47.50 | Generic · Prescription | GLOBAL PHARMA | Valid |
| SARTAN 50 mg Film coated Tablets | 50 mg | Film-coated tablet · Oral use | 30 Blister | SAR 40.80 | Generic · Prescription | GLOBAL PHARMA | Valid |
| SORTIVA 50 MG FILM COATED TABLETS | 50 mg | Film-coated tablet · Oral use | 30 Blister | SAR 45.35 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| SORTIVA FORTE 100MG F.C. TABLETS | 100 mg | Film-coated tablet · Oral use | 30 Blister | SAR 52.80 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| STRAVIS 50MG FILM COATED TABLETS | 50 mg | Film-coated tablet · Oral use | 28 Blister | SAR 40.80 | Generic · Prescription | RIYADH PHARMA | Valid |
| LOSANET 100 mg Tablet | 100 mg | Tablet · Oral use | 30 Blister | SAR 79.10 | Generic · Prescription | PHARMALINE | Suspended · Not Marketed |
| LOSANET 50 mg Tablet | 50 mg | Tablet · Oral use | 30 Blister | SAR 48.25 | Generic · Prescription | PHARMALINE | Suspended · Not Marketed |
| SORTIVA 25 MG FILM COATED TABLETS | 25 mg | Film-coated tablet · Oral use | 30 Blister | SAR 29.20 | Generic · Prescription | SPIMACO ADDWAEIH | Invalid · Not Marketed |
| STRAVIS 100MG FILM COATED TABLETS | 100 mg | Film-coated tablet · Oral use | 28 Blister | SAR 47.50 | Generic · Prescription | RIYADH PHARMA | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
CARDIOMYOPATHY; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; HYPERTENSION; RAYNAUD'S PHENOMENON; SICKLE CELL DISEASE - ALBUMINURIA MANAGEMENT; SYSTEMIC LUPUS ERYTHEMATOSUS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| COZAAR | 25MG; 50MG; 100MG | tablet · oral | ORGANON | Prescription | 14 Apr 1995 |
| LOSARTAN POTASSIUM | 25MG; 50MG; 100MG | tablet · oral | CHARTWELL RX | Prescription | 6 Oct 2010 |
| LOSARTAN POTASSIUM | 25MG; 50MG; 100MG | tablet · oral | LUPIN LTD | Prescription | 6 Oct 2010 |
| LOSARTAN POTASSIUM | 25MG; 50MG; 100MG | tablet · oral | ZYDUS PHARMS USA INC | Prescription | 6 Oct 2010 |
| LOSARTAN POTASSIUM | 25MG; 50MG; 100MG | tablet · oral | AUROBINDO PHARMA | Prescription | 6 Oct 2010 |
| LOSARTAN POTASSIUM | 25MG; 50MG; 100MG | tablet · oral | STRIDES PHARMA | Prescription | 6 Oct 2010 |
| LOSARTAN POTASSIUM | 25MG; 50MG; 100MG | tablet · oral | ALEMBIC PHARMS LTD | Prescription | 6 Oct 2010 |
| LOSARTAN POTASSIUM | 25MG; 50MG; 100MG | tablet · oral | AIPING PHARM INC | Prescription | 6 Oct 2010 |
| LOSARTAN POTASSIUM | 25MG; 50MG; 100MG | tablet · oral | WATSON LABS | Prescription | 6 Oct 2010 |
| LOSARTAN POTASSIUM | 25MG; 50MG; 100MG | tablet · oral | PRINSTON INC | Prescription | 6 Jun 2011 |
| LOSARTAN POTASSIUM | 25MG; 50MG; 100MG | tablet · oral | MACLEODS PHARMS LTD | Prescription | 30 May 2012 |
| LOSARTAN POTASSIUM | 25MG; 50MG; 100MG | tablet · oral | JUBILANT CADISTA | Prescription | 18 Sep 2012 |
| LOSARTAN POTASSIUM | 25MG; 50MG; 100MG | tablet · oral | HETERO LABS LTD V | Prescription | 12 Aug 2015 |
| LOSARTAN POTASSIUM | 25MG; 50MG; 100MG | tablet · oral | UNICHEM | Prescription | 14 Oct 2015 |
| LOSARTAN POTASSIUM | 25MG; 50MG; 100MG | tablet · oral | GRANULES | Prescription | 23 Feb 2023 |
| LOSARTAN POTASSIUM | 25MG; 50MG; 100MG | tablet · oral | MSN | Prescription | 14 Aug 2023 |
| ARBLI | 10MG/ML | suspension · oral | SCIENTURE | Prescription | 13 Mar 2025 |
| LOSARTAN POTASSIUM | 25MG; 50MG; 100MG | tablet · oral | GRAVITI PHARMS | Prescription | 19 Sep 2025 |
| LOSARTAN POTASSIUM | 25MG; 50MG; 100MG | tablet · oral | TEVA | Discontinued | 6 Apr 2010 |
| LOSARTAN POTASSIUM | 25MG; 50MG; 100MG | tablet · oral | HIKMA PHARMS | Discontinued | 6 Oct 2010 |
| LOSARTAN POTASSIUM | 25MG; 50MG; 100MG | tablet · oral | TORRENT PHARMS | Discontinued | 6 Oct 2010 |
| LOSARTAN POTASSIUM | 25MG; 50MG; 100MG | tablet · oral | APOTEX CORP | Discontinued | 6 Oct 2010 |
| LOSARTAN POTASSIUM | 25MG; 50MG; 100MG | tablet · oral | MYLAN | Discontinued | 6 Oct 2010 |
| LOSARTAN POTASSIUM | 25MG; 50MG; 100MG | tablet · oral | MICRO LABS | Discontinued | 24 Sep 2012 |
| LOSARTAN POTASSIUM | 25MG; 50MG; 100MG | tablet · oral | IPCA LABS LTD | Discontinued | 30 Aug 2013 |
2 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| AURO-LOSARTAN | 02403323 | 25.0 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-LOSARTAN | 02403331 | 50.0 MG | TABLET · ORAL | AURO PHARMA INC |
| AURO-LOSARTAN | 02403358 | 100.0 MG | TABLET · ORAL | AURO PHARMA INC |
| COZAAR | 02182815 | 25 MG | TABLET · ORAL | ORGANON CANADA INC. |
| COZAAR | 02182874 | 50 MG | TABLET · ORAL | ORGANON CANADA INC. |
| COZAAR | 02182882 | 100 MG | TABLET · ORAL | ORGANON CANADA INC. |
| JAMP-LOSARTAN | 02398834 | 25 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP-LOSARTAN | 02398842 | 50 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| JAMP-LOSARTAN | 02398850 | 100 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| LOSARTAN | 02388790 | 25 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| LOSARTAN | 02388804 | 50 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| LOSARTAN | 02388812 | 100 MG | TABLET · ORAL | SIVEM PHARMACEUTICALS ULC |
| LOSARTAN | 02388863 | 25 MG | TABLET · ORAL | SANIS HEALTH INC |
| LOSARTAN | 02388871 | 50 MG | TABLET · ORAL | SANIS HEALTH INC |
| LOSARTAN | 02388898 | 100 MG | TABLET · ORAL | SANIS HEALTH INC |
| MINT-LOSARTAN | 02405733 | 25 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
| MINT-LOSARTAN | 02405741 | 50 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
| MINT-LOSARTAN | 02405768 | 100 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
| PMS-LOSARTAN | 02309750 | 25 MG | TABLET · ORAL | PHARMASCIENCE INC |
| PMS-LOSARTAN | 02309769 | 50 MG | TABLET · ORAL | PHARMASCIENCE INC |
| PMS-LOSARTAN | 02309777 | 100 MG | TABLET · ORAL | PHARMASCIENCE INC |
| SANDOZ LOSARTAN | 02313332 | 25 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| SANDOZ LOSARTAN | 02313340 | 50 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| SANDOZ LOSARTAN | 02313359 | 100 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| TEVA-LOSARTAN | 02357968 | 50 MG | TABLET · ORAL | TEVA CANADA LIMITED |
2 more — full table
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | COZAAR 100 MG TABLET | $6.13999 | per EA | 23 Sep 2026 |
| US NADAC | COZAAR 25 MG TABLET | $3.36363 | per EA | 23 Sep 2026 |
| US NADAC | COZAAR 50 MG TABLET | $4.49351 | per EA | 23 Sep 2026 |
| US NADAC | LOSARTAN POTASSIUM 100 MG TAB | $0.04453 | per EA | 23 Sep 2026 |
| US NADAC | LOSARTAN POTASSIUM 25 MG TAB | $0.02183 | per EA | 23 Sep 2026 |
| US NADAC | LOSARTAN POTASSIUM 50 MG TAB | $0.03267 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Losartan 100mg tablets | £0.95 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Losartan 12.5mg tablets | £1.26 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Losartan 25mg tablets | £0.72 | 28 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Losartan 50mg tablets | £0.81 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 12.3. Antihypertensive medicines · core
Essential hypertension
Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet - 12.4. Medicines used in heart failure · core
Heart failure
Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
Safety signals and safety-related labeling changes
- US FDA 18 Feb 2026 ARBLI — safety-related labeling change
Labeling sections changed: Adverse Reactions - US FDA 20 Jun 2025 COZAAR — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 20 Jun 2025 HYZAAR — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Combinations containing Losartan
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.